Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Lett Appl Microbiol ; 66(5): 362-367, 2018 May.
Article in English | MEDLINE | ID: mdl-29432641

ABSTRACT

Magnetotactic bacteria (MTB) have the unique ability to produce magnetic particles surrounded by a biomembrane to form the magnetosome organelle. Therefore, MTB have novel physical and magnetic properties and have consequently been used in several biotechnological applications. The magnetic properties of these micro-organisms and their magnetosomes have, however, never been used for the generation of electricity as described in this letter. Comparisons were made between, firstly, the electricity generated from purified magnetosomes, MTB culture (bacterial cells with magnetosomes) and sterile, liquid growth medium (control). Secondly, the electricity generated by a dilution series of purified magnetosomes were compared. A statistically significant difference was found between the voltage measured from the purified magnetosomes (highest voltage), MTB culture (lower voltage) and liquid growth medium (lowest voltage). In the dilution series, the voltage measured increased as the magnetosome concentration increased, but only up to an optimum concentration (0·0376 mg ml-1 ). In this study, we have demonstrated that a significantly higher voltage than that of the control could be measured when MTB or purified magnetosomes were pumped through a solenoid by applying Faraday's law of electromagnetic induction. SIGNIFICANCE AND IMPACT OF THE STUDY: This study provides proof-of-concept of electromagnetic induction using magnetosomes or magnetotactic bacteria in an experimental setup based on the law of Faraday. The concept of using these bacteria or their biomineralized magnetic nanoparticles as a biological alternative in low voltage electricity generation has the potential to be further explored and developed.


Subject(s)
Electricity , Electromagnetic Phenomena , Magnetosomes/metabolism , Magnetospirillum/metabolism , Magnetite Nanoparticles , Proof of Concept Study
2.
Biomaterials ; 121: 167-178, 2017 03.
Article in English | MEDLINE | ID: mdl-28088078

ABSTRACT

We investigate here the potential of single step production of genetically engineered magnetosomes, bacterial biogenic iron-oxide nanoparticles embedded in a lipid vesicle, as a new tailorable magnetic resonance molecular imaging probe. We demonstrate in vitro the specific binding and the significant internalization into U87 cells of magnetosomes decorated with RGD peptide. After injection at the tail vein of glioblastoma-bearing mice, we evidence in the first 2 h the rapid accumulation of both unlabeled and functionalized magnetosomes inside the tumor by Enhanced Permeability and Retention effects. 24 h after the injection, a specific enhancement of the tumor contrast is observed on MR images only for RGD-labeled magnetosomes. Post mortem acquisition of histological data confirms MRI results with more magnetosomes found into the tumor treated with functionalized magnetosomes. This work establishes the first proof-of-concept of a successful bio-integrated production of molecular imaging probe for MRI.


Subject(s)
Biomarkers, Tumor/metabolism , Brain Neoplasms/metabolism , Genetic Enhancement/methods , Magnetosomes/chemistry , Magnetosomes/genetics , Molecular Imaging/methods , Oligopeptides/pharmacokinetics , Animals , Brain Neoplasms/pathology , Cell Line, Tumor , Contrast Media/chemistry , Magnetic Resonance Imaging/methods , Magnetosomes/ultrastructure , Mice , Molecular Probe Techniques , Molecular Probes/chemistry , Nanoconjugates/chemistry , Nanoconjugates/ultrastructure , Oligopeptides/chemistry , Tissue Distribution
3.
Biochimie ; 88(11): 1651-63, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16806635

ABSTRACT

The presence of heavy metal(loid)s in soils and waters is an important issue with regards to human health. Taking into account speciation problems, in the first part of this report, we investigated under identical growth conditions, yeast tolerance to a set of 15 cytotoxic metal(loid)s and radionuclides. The yeast cadmium factor 1 (YCF1) is an ATP-Binding Cassette transporter mediating the glutathione detoxification of heavy metals. In the second part, metal(loid)s that could be handled by YCF1 and a possible re-localisation of the transporter after heavy metal exposure were evaluated. YCF1 and a C-terminal GFP fusion, YCF1-GFP, were overexpressed in wild-type and Deltaycf1 strains. Both forms were functional, conferring a tolerance to Cd, Sb, As, Pb, Hg but not to Ni, Zn, Cu, Ag, Se, Te, Cr, Sr, Tc, U. Confocal experiments demonstrated that during exposure to cytotoxic metals, the localisation of YCF1-GFP was restricted to the yeast vacuolar membrane. In the last part, the role of glutathione in this resistance mechanism to metal(loid)s was studied. In the presence of heavy metals, application of buthionine sulfoximine (BSO), a well-known inhibitor of gamma-glutamylcysteine synthetase, led to a decrease in the cytosolic pool of GSH and to a limitation of yeast growth. Surprisingly, BSO was able to phenocopy the deletion of gamma-glutamylcysteine synthetase after exposure to Cd but not to Sb or As. In the genetic context of gsh1 and gsh2 yeast mutants, the critical role of GSH for Cd, As, Sb and Hg tolerance was compared to that of wild-type and Deltaycf1.


Subject(s)
ATP-Binding Cassette Transporters/metabolism , Buthionine Sulfoximine/pharmacology , Glutathione/metabolism , Metals/toxicity , Radioisotopes/toxicity , Saccharomyces cerevisiae Proteins/metabolism , Saccharomyces cerevisiae/drug effects , ATP-Binding Cassette Transporters/drug effects , ATP-Binding Cassette Transporters/genetics , Inactivation, Metabolic , Mercuric Chloride/toxicity , Plasmids , Recombinant Fusion Proteins/metabolism , Saccharomyces cerevisiae/cytology , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae Proteins/drug effects , Saccharomyces cerevisiae Proteins/genetics
4.
Virology ; 282(1): 176-85, 2001 Mar 30.
Article in English | MEDLINE | ID: mdl-11259200

ABSTRACT

The virion-associated Vpr protein of human immunodeficiency virus type 1 (HIV-1) alters cell cycle progression from the G2 phase, influences the virus in vivo mutation rate, and participates in the nuclear translocation of viral DNA. While many Vpr-interacting proteins have been identified, the functional relevance of these interactions remains to be thoroughly documented. We have explored the contribution of the interaction of HIV-1 Vpr with HHR23A, a cellular protein implicated in DNA repair, to the known phenotypes of Vpr. The association of Vpr with HHR23A required the core region of Vpr, which encompasses the two alpha-helical structures of the protein. No binding of HHR23A was detected with the Vpr and Vpx proteins of other primate lentiviruses. HIV-1 Vpr variants containing single amino acid substitutions in each alpha-helix and deficient for binding to HHR23A were isolated. The functional characterization of these Vpr variants indicated that binding to HHR23A did not correlate with the ability of Vpr to induce cell cycle arrest, even though it was previously proposed that HHR23A is a mediator of the Vpr-induced G2 arrest. Also, the Vpr-HHR23A interaction did not influence the HIV-1 in vivo mutation rate. Finally, Vpr and HHR23A are both localized in the nucleus, but no correlation was observed between the nuclear targeting of Vpr and the interaction with HHR23A. Further analysis is needed to determine the functional role(s) of the Vpr-HHR23A association during the HIV-1 life cycle.


Subject(s)
DNA Repair , DNA-Binding Proteins/metabolism , Gene Products, vpr/metabolism , HIV-1/metabolism , Retroviridae Proteins/metabolism , Amino Acid Substitution , Animals , COS Cells , Cell Cycle , Cell Nucleus/metabolism , DNA Repair Enzymes , Genetic Vectors , HeLa Cells , Humans , Transfection , Virus Replication , vpr Gene Products, Human Immunodeficiency Virus
5.
J Virol ; 74(15): 7039-47, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10888643

ABSTRACT

The Vpr protein of human immunodeficiency virus type 1 (HIV-1) influences the in vivo mutation rate of the virus. Since Vpr interacts with a cellular protein implicated in the DNA repair process, uracil DNA glycosylase (UNG), we have explored the contribution of this interaction to the mutation rate of HIV-1. Single-amino-acid variants of Vpr were characterized for their differential UNG-binding properties and used to trans complement vpr null mutant HIV-1. A striking correlation was established between the abilities of Vpr to interact with UNG and to influence the HIV-1 mutation rate. We demonstrate that Vpr incorporation into virus particles is required to influence the in vivo mutation rate and to mediate virion packaging of the nuclear form of UNG. The recruitment of UNG into virions indicates a mechanism for how Vpr can influence reverse transcription accuracy. Our data suggest that distinct mechanisms evolved in primate and nonprimate lentiviruses to reconcile uracil misincorporation into lentiviral DNA.


Subject(s)
DNA Glycosylases , Gene Products, vpr/metabolism , HIV-1/genetics , Mutation , N-Glycosyl Hydrolases/metabolism , Animals , Base Sequence , COS Cells , Cell Nucleus/enzymology , Gene Products, vpr/genetics , Genetic Complementation Test , Genetic Vectors , HIV-1/physiology , HeLa Cells , Humans , Molecular Sequence Data , Two-Hybrid System Techniques , Uracil-DNA Glycosidase , Virion/metabolism , Virus Replication , vpr Gene Products, Human Immunodeficiency Virus
6.
Biochem Pharmacol ; 59(6): 655-63, 2000 Mar 15.
Article in English | MEDLINE | ID: mdl-10677582

ABSTRACT

Hexitol nucleic acid (HNA) is a new steric blocking oligonucleotide, hybridizing sequence selectively with RNA. The biological activity of HNA was evaluated in an in vitro translation arrest system targeting Ha-ras mRNA and in a cellular system targeting intracellular adhesion molecule-1 (ICAM-1) expression. HNA very efficiently and selectively inhibited Ha-ras mRNA translation (IC(50) of 50 nM) when targeted at the translation initiation region. When targeting at the 12th codon region, a gap-mer approach was needed to inhibit mRNA translation. Similarly, HNA inhibited ICAM-1 expression in keratinocytes when targeting at codon sequences. In this test system, HNA is less active but more selective than phosphorothioates, but needs lipofection to become active in keratinocytes. This new steric blocker may be an efficient antisense agent providing that enough material can be brought into cells.


Subject(s)
Genes, ras/drug effects , Intercellular Adhesion Molecule-1/drug effects , Oligonucleotides/pharmacology , Cells, Cultured , Cytokines/pharmacology , Gene Expression/drug effects , Genes, ras/genetics , Humans , Intercellular Adhesion Molecule-1/genetics , Keratinocytes/drug effects , Keratinocytes/metabolism , Oligonucleotides/chemistry , Protein Biosynthesis/drug effects , RNA, Messenger/drug effects
7.
J Virol ; 73(1): 592-600, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9847364

ABSTRACT

Vpr and Vpx proteins from human and simian immunodeficiency viruses (HIV and SIV) are incorporated into virions in quantities equivalent to those of the viral Gag proteins. We demonstrate here that Vpr and Vpx proteins from distinct lineages of primate lentiviruses were able to bind to their respective Gag precursors. The capacity of HIV type 1 (HIV-1) Vpr mutants to bind to Pr55(Gag) was correlated with their incorporation into virions. Molecular analysis of these interactions revealed that they required the C-terminal p6 domain of the Gag precursors. While the signal for HIV-1 Vpr binding lies in the leucine triplet repeat region of the p6 domain reported to be essential for incorporation, SIVsm Gag lacking the equivalent region still bound to SIVsm Vpr and Vpx, indicating that the determinants for Gag binding are located upstream of this region of the p6 domain. Binding to Gag cleavage products showed that HIV-1 Vpr interacted directly with the nucleocapsid protein (NC), whereas SIVsm Vpr and Vpx did not interact with NC but with the p6 protein. These results (i) reveal differences between HIV-1 and SIVsm for the p6 determinants required for Vpr and Vpx binding to Gag and (ii) suggest that HIV-1 Vpr and SIVsm Vpr and Vpx interact with distinct cleavage products of the precursor following proteolytic processing in the virions.


Subject(s)
Gene Products, gag/metabolism , Gene Products, vpr/metabolism , HIV/metabolism , Protein Precursors/metabolism , Simian Immunodeficiency Virus/metabolism , Viral Regulatory and Accessory Proteins/metabolism , Virion/metabolism , Amino Acid Sequence , Humans , Molecular Sequence Data , Repetitive Sequences, Amino Acid , vpr Gene Products, Human Immunodeficiency Virus
SELECTION OF CITATIONS
SEARCH DETAIL
...